MD4748C1 - Terapii imunooncolitice - Google Patents
Terapii imunooncoliticeInfo
- Publication number
- MD4748C1 MD4748C1 MDA20180086A MD20180086A MD4748C1 MD 4748 C1 MD4748 C1 MD 4748C1 MD A20180086 A MDA20180086 A MD A20180086A MD 20180086 A MD20180086 A MD 20180086A MD 4748 C1 MD4748 C1 MD 4748C1
- Authority
- MD
- Moldova
- Prior art keywords
- oncolytic vaccinia
- immunity
- immuno
- reduces
- gene
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000700618 Vaccinia virus Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000005875 antibody response Effects 0.000 abstract 2
- 230000000174 oncolytic effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 abstract 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 abstract 1
- 102000005348 Neuraminidase Human genes 0.000 abstract 1
- 108010006232 Neuraminidase Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 abstract 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 230000007236 host immunity Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 102000044166 interleukin-18 binding protein Human genes 0.000 abstract 1
- 108010070145 interleukin-18 binding protein Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Invenţia se referă la virusuri oncolitice de vaccin variolic, modificate pentru a stimula imunitatea antitumorală şi/sau a diminua imunitatea gazdei şi/sau răspunsul anticorpilor gazdei împotriva virusului. Invenţia se bazează, cel puţin parţial, pe descoperirea că virusul oncolitic de vaccin variolic (i) purtând o deleţie genomică a genei, care reduce imunitatea celulelor T (proteina de legare a interleukinei-18); (ii) tratat cu enzima sialidază, care se crede că reduce activarea TLR2 şi, astfel, răspunsul anticorpilor; (iii) care poartă gena care amplifică inducerea limfocitelor T citotoxice (de exemplu TRIF) şi/sau (iv) care reduce numărul de celule supresoare de origine mieloidă în tumoare prin reducerea cantităţii de prostaglandină E2, reduce creşterea tumorii. Astfel, prezenta invenţie se referă la virusuri imunooncolitice de vaccin variolic şi la metode de utilizare a acestora în tratamentul tumorilor maligne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20180086A2 MD20180086A2 (ro) | 2019-03-31 |
| MD4748B1 MD4748B1 (ro) | 2021-02-28 |
| MD4748C1 true MD4748C1 (ro) | 2021-09-30 |
Family
ID=52484194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20180086A MD4748C1 (ro) | 2013-08-22 | 2014-08-22 | Terapii imunooncolitice |
| MD20160027A MD4624C1 (ro) | 2013-08-22 | 2014-08-22 | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MD20160027A MD4624C1 (ro) | 2013-08-22 | 2014-08-22 | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (ro) |
| EP (3) | EP3036329B1 (ro) |
| JP (3) | JP6912199B2 (ro) |
| KR (1) | KR102389240B1 (ro) |
| CN (1) | CN105658795B (ro) |
| AU (1) | AU2014308648B2 (ro) |
| CA (3) | CA3213715A1 (ro) |
| DK (2) | DK3778897T3 (ro) |
| EA (1) | EA037582B1 (ro) |
| ES (2) | ES2847305T3 (ro) |
| FI (1) | FI3778897T3 (ro) |
| HK (1) | HK1223402A1 (ro) |
| HR (1) | HRP20240078T1 (ro) |
| IL (1) | IL243996A0 (ro) |
| LT (1) | LT3778897T (ro) |
| MD (2) | MD4748C1 (ro) |
| MX (1) | MX2016002257A (ro) |
| NZ (1) | NZ716825A (ro) |
| PE (1) | PE20160673A1 (ro) |
| PH (1) | PH12016500329A1 (ro) |
| PL (1) | PL3778897T3 (ro) |
| PT (1) | PT3778897T (ro) |
| RS (1) | RS65104B1 (ro) |
| SG (1) | SG11201600960PA (ro) |
| SI (1) | SI3778897T1 (ro) |
| WO (1) | WO2015027163A1 (ro) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ716825A (en) * | 2013-08-22 | 2022-02-25 | Univ Pittsburgh Commonwealth Sys Higher Education | Immuno-oncolytic therapies |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| WO2016168862A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| WO2017014296A1 (ja) * | 2015-07-22 | 2017-01-26 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| JP6895968B2 (ja) * | 2015-09-08 | 2021-06-30 | シルラジェン インコーポレイテッド | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| MX2018010204A (es) | 2016-02-25 | 2019-05-06 | Memorial Sloan Kettering Cancer Center | Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| KR20190007416A (ko) * | 2016-03-25 | 2019-01-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 합성적으로 엔벨롭된 바이러스 |
| EP3254692A1 (en) | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| EP3488005A4 (en) | 2016-07-19 | 2020-07-29 | University of Pittsburgh- Of the Commonwealth System of Higher Education | TARGETING ONCOLYTIC VIRUSES STAT3 |
| AU2017332367B2 (en) * | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| EP3577132A4 (en) * | 2017-02-03 | 2021-03-10 | University of Pittsburgh - of The Commonwealth System of Higher Education | ONCOLYTIC VIRUS THERAPY |
| US20180252729A1 (en) * | 2017-03-06 | 2018-09-06 | University Of Louisville Research Foundation | Methods and compositions for determining the potency of a therapeutic cellular composition |
| WO2018195552A1 (en) * | 2017-04-21 | 2018-10-25 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| CA3081436A1 (en) * | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| WO2019106205A1 (en) | 2017-12-01 | 2019-06-06 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| CN112020510A (zh) | 2018-03-19 | 2020-12-01 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| JP2021531042A (ja) * | 2018-07-20 | 2021-11-18 | アンサン バイオファーマ, インク.Ansun Biopharma, Inc. | 癌細胞、免疫細胞及び腫瘍微小環境へのシアリダーゼの送達 |
| CA3124287A1 (en) * | 2018-12-21 | 2020-06-25 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
| EP3908650A4 (en) * | 2019-01-07 | 2022-10-19 | KaliVir Immunotherapeutics, Inc. | METHODS OF TREATMENT OF CANCER |
| US11529402B2 (en) * | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| WO2020165730A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CA3163805A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| US20230201283A1 (en) * | 2020-01-09 | 2023-06-29 | Pfizer Inc. | Recombinant vaccinia virus |
| EP4329786A1 (en) | 2021-04-30 | 2024-03-06 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| EP4363059A1 (en) * | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| JPWO2007023725A1 (ja) * | 2005-08-25 | 2009-02-26 | 公立大学法人横浜市立大学 | 遺伝子ワクチン |
| JP2009507853A (ja) * | 2005-09-07 | 2009-02-26 | ジェンネレックス インコーポレイティッド | Ｇｍ−ｃｓｆ発現ポックスウイルスを用いる転移性および／または全身播種性癌の全身処置 |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| ES2671570T3 (es) | 2009-09-14 | 2018-06-07 | Sillajen Biotherapeutics, Inc. | Terapia combinada contra el cáncer con virus oncolítico de vaccinia |
| US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
| CA2836299A1 (en) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| NZ716825A (en) | 2013-08-22 | 2022-02-25 | Univ Pittsburgh Commonwealth Sys Higher Education | Immuno-oncolytic therapies |
-
2014
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en active Application Filing
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active IP Right Grant
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en active Pending
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
- 2016-10-12 HK HK16111742.0A patent/HK1223402A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500329A1 (en) | Immuno-oncolytic therapies | |
| PH12017501942A1 (en) | Oncolytic adenovirus encoding a b7 protein | |
| PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
| MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
| MD4655C1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| MX2017004691A (es) | Bloqueo de cd73. | |
| MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
| MX2015015638A (es) | Metodos para diseñar celulas t altamente activas para inmunoterapia. | |
| EP2536821A4 (en) | IMPROVING THE ACTIVITY OF PROTEINS REQUIRING AGGREGATE FE-S | |
| AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
| MX2021008392A (es) | Neoantígenos prostaticos y sus usos. | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
| MD4480C1 (ro) | Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia | |
| MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
| WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
| RU2016121425A (ru) | Получение вирусного вектора | |
| MX2017003881A (es) | Enzima solubilizada y usos de la misma. | |
| RU2012111004A (ru) | Способ использования рибонуклеазы bacillus intermedius | |
| EA202191919A1 (ru) | Неоантигены предстательной железы и их применение | |
| MY185846A (en) | Oncolytic adenovirus encoding a b7 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued |